Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma

The purpose of the study is to understand whether study drugs domvanalimab and zimberelimab are safe and effective in combination with standard chemotherapy for patients with operable cancer of the esophagus, stomach, or gastroesophageal junction (where the stomach meets the esophagus). All participants will receive the study treatment. Participants will receive chemotherapy and two immune therapies drugs (domvanalimab and zimberelimab) for up to 4 months before surgery. After surgery and at least a 4 week recovery, participants will receive domvanalimab and zimberelimab for up to 8 months. After completion of the study treatment, participants will be followed for up to 5 years per standard of care.

NCT Number	NCT07283848
Lead Sponsor	Massachusetts General Hospital Collaborators: Arcus Biosciences, Inc., Gateway for Cancer Research
Conditions	Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction
Start Date	2026-02-01
Primary Completion	2026-12-01 (estimated)
Study Completion	2029-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-26